ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

Small Business Technology Transfer Program Solicitation

June 23, 1995

In Brief: Indiana U. Planning “World Class” Cancer Center; UCLA Names Two New Cancer Control Directors

June 6, 1986

ASCO Guideline On Breast Cancer Risk Reduction Updated

May 29, 2009

In Brief: Columiba Adds Presbyterian to Center’s Name: Clinton’s Mother Honored; DeVita move Rumored

March 5, 1993

FDA Didn’t Tell Advisors About Data Linking Obesity Drug With Precancerous Lesions.

June 2, 2006

NCI Communications Director Sieber To Retire; Science Planner Waldrop Also To Leave NCI.

September 14, 2001